<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-six patients with <z:hpo ids='HP_0011009'>acute</z:hpo> supratentorial <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> were randomly allocated to double-blind intravenous treatment with the calcium entry blocker flunarizine (12 patients) or placebo (14 patients) within 24 h </plain></SENT>
<SENT sid="1" pm="."><plain>CT scan excluded other significant pathology </plain></SENT>
<SENT sid="2" pm="."><plain>Impaired consciousness and gaze deviation were more common in the placebo group </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients in the treated group (25%) were either dead or severely disabled after 6 months, whereas this occurred in 8 of the 14 (57%) control patients, a difference of 32% </plain></SENT>
<SENT sid="4" pm="."><plain>This difference is not statistically significant and there is an uneven distribution of important prognostic variables, however, the confidence limits of the difference (-4% and +68%) suggest that there may be a clinically important effect </plain></SENT>
</text></document>